Research and Markets: Anti-cancer Drugs Market in Japan 2011-2015

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/txzrzq/anticancer_drugs) has announced the addition of the "Anti-cancer Drugs Market in Japan 2011-2015" report to their offering.

Overview

TechNavio's analysts forecast the Anti-cancer Drugs market in Japan to grow at a CAGR of 11.1 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increase in the number of cancer patients in the country. The Anti-cancer Drugs market in Japan has also been witnessing the trend of using a combination of cancer therapies for treatment. However, stringent government regulations in Japan could pose a challenge to the growth of this market.

This report, the Anti-cancer Drugs Market in Japan 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report focuses on Japan; it discusses the Anti-cancer drugs market in the Japan landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this market space include Roche Pharmaceuticals Inc., Novartis International AG, Takeda Pharmaceutical Co. Ltd., Eli Lilly and Co., and AstellasPharma Inc.

Key questions answered in this report:

-What will the market size be in 2015 and at what rate will it grow?

-What key trends is this market subject to?

-What is driving this market?

See the original post here:
Research and Markets: Anti-cancer Drugs Market in Japan 2011-2015